The Cross-Portfolio Strategic Integration team drives sustainability of the BMS Research Portfolio by guiding impactful decision-making and assessing opportunities to improve effective and efficient progression of research assets to clinical development.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development, and across all therapeutic areas at BMS.

The Pharmaceutical Candidate Optimization organization at Bristol Myers Squibb is a dynamic, multi-disciplinary department that works to discover and optimize new drug candidates. We work across all therapeutic areas and all modalities (small molecules, biotherapeutics, gene and cell therapies and other novel modalities), and engage with all other R&D functions to advance new assets in the BMS portfolio. Our integrated, cross-functional teams apply deep expertise in drug metabolism, pharmacokinetics (DMPK), toxicology, pharmaceutics and bioanalysis to identify and solve issues, discover high quality drug candidates, and enable their clinical development.

Chemistry is a core capability in Small Molecule and Drug Discovery (SMDD) with innovative scientists working in medicinal chemistry, radiochemistry, analytical chemistry and large-scale synthesis. Within SMDD, our Lead Discovery and Optimization (LDO) team is responsible for high throughput screening, compound storage and distribution, primary assays to support discovery programs, and compound profiling to explore drug liabilities in vitro.

The Thematic Research Center Immunology and Cardiovascular (ICV) at BMS is one of the fundamental Research units delivering therapeutics to patients. Our mission is to create transformative medicines of tomorrow based on the cutting-edge science of today. We leverage BMS’s internal invention engine that includes industry-leading expertise in small molecule chemistry, protein biotherapeutics, cell therapy, protein degradation, nucleic acids, and other therapeutic modalities.

The Thematic Research Center Immuno-Oncology and Cell Therapy is one of the fundamental research engines delivering therapeutics to patients. Our mission is to drive leadership in the use of immune effector cell-based therapies in hematological and solid cancers. More specifically, we are focused on developing engineered cell-based therapies, as well as biotherapeutics, both aimed at harnessing the power of immune cells to mediate anti-tumor activity.

Thematic Research Center Integrative Sciences (IS) has an external focus within the Research division at BMS. The IS group has three principal responsibilities: (i) creating Discovery Stage collaborations within the Biotech Ecosystem, (ii) facilitating conversion of academic concepts to industry workable ideas via incubator constructs, and (iii) supporting BMS scientists’ collaborations with academic investigators.

The Thematic Research Center Mechanisms of Cancer Resistance at BMS is one of the fundamental research and early development engines delivering oncology therapeutics to patients. The scientists at this state-of-the-art research and development site in Cambridge focus on novel tumor intrinsic targets and pathways for tumors that are refractory to current Immuno-Oncology and Oncology therapies, and implement our discovery platforms across all of our therapeutic areas of focus.

The Thematic Research Center Neuroscience is committed to development of transformational therapeutics for patients with neurodegenerative and neuromuscular diseases. We have built a network of external partnerships across multiple treatment modalities (small molecules, biologics and RNA targeting) that leverage our leadership in protein homeostasis and inflammation to attach neurological diseases. Internal research focuses on protein homeostasis by direct and ligand- directed degradation, neuroinflammation and remyelination.

Sitting at the intersection of Research and Drug Development, Translational Medicine is a passionate community of scientists and related professionals dedicated to driving the science that enables us to target the right treatment to the right patient at the right dose. We utilize the power of translational science to unlock the unique traits of each individual to inform practitioners about how to use BMS medicines to address unmet medical needs, and to identify new ways we can target disease to advance our portfolio.

The Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis team at BMS is responsible for the pharmacology and pharmacometric support for all pipeline assets throughout the clinical development lifecycle. Composed of pharmacologists, pharmacometricians and modelers, this group oversees the pharmacokinetic evaluation, pharmacometric exposure-response evaluation, quantitative systems pharmacology modeling, physiologically-based pharmacokinetic modeling and model-based meta-analysis of assets covering all platforms of therapies, including small molecules, traditional and complex biologics and next gen cell therapies. All therapeutic areas are supported. The Clinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis team interacts with discovery and translational scientists, project leadership, early development, late development and commercial colleagues to optimize dosing, formulation, delivery and combination strategies to enable faster and more effective drug development informed by core scientific principals and data.

The Cross-Portfolio Strategic Integration team drives sustainability of the BMS Research Portfolio by guiding impactful decision-making and assessing opportunities to improve effective and efficient progression of research assets to clinical development.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development, and across all therapeutic areas at BMS.

The Pharmaceutical Candidate Optimization organization at Bristol Myers Squibb is a dynamic, multi-disciplinary department that works to discover and optimize new drug candidates. We work across all therapeutic areas and all modalities (small molecules, biotherapeutics, gene and cell therapies and other novel modalities), and engage with all other R&D functions to advance new assets in the BMS portfolio. Our integrated, cross-functional teams apply deep expertise in drug metabolism, pharmacokinetics (DMPK), toxicology, pharmaceutics and bioanalysis to identify and solve issues, discover high quality drug candidates, and enable their clinical development.

The Non-Clinical Safety and Veterinary Sciences organization enables the safe conduct of clinical studies and marketing applications while applying the core underlying principles of robust science & problem solving, 3R’s (reduce, replace and refine), animal welfare, and quality & compliance to our nonclinical efforts. While focusing on transforming patients’ lives through science, we intend to be an industry-leading nonclinical safety evaluation, laboratory animal science and medicine organization with high scientific, quality, and employee safety standards.

Chemistry is a core capability in Small Molecule and Drug Discovery (SMDD) with innovative scientists working in medicinal chemistry, radiochemistry, analytical chemistry and large-scale synthesis. Within SMDD, our Lead Discovery and Optimization (LDO) team is responsible for high throughput screening, compound storage and distribution, primary assays to support discovery programs, and compound profiling to explore drug liabilities in vitro.

Thematic Research Center Integrative Sciences (IS) has an external focus within the Research division at BMS. The IS group has three principal responsibilities: (i) creating Discovery Stage collaborations within the Biotech Ecosystem, (ii) facilitating conversion of academic concepts to industry workable ideas via incubator constructs, and (iii) supporting BMS scientists’ collaborations with academic investigators.

Sitting at the intersection of Research and Drug Development, Translational Medicine is a passionate community of scientists and related professionals dedicated to driving the science that enables us to target the right treatment to the right patient at the right dose. We utilize the power of translational science to unlock the unique traits of each individual to inform practitioners about how to use BMS medicines to address unmet medical needs, and to identify new ways we can target disease to advance our portfolio.

The Discovery Biotherapeutics team at BMS seeks to understand the structure and function of complex molecules such as bispecific antibodies, antibody drug conjugates and endogenous proteins in order to optimize their utility as therapeutic agents. We collaborate with biology and translational scientists embedded in the Thematic Research Centers in order to prosecute Targets and Biological pathways with disease-modifying potential. By using a blend of internal and external technologies and capabilities, we work to discover and deliver first-in-class as well as best-in-class molecules that warrant clinical evaluation for patient benefit.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development, and across all therapeutic areas at BMS.

The Pharmaceutical Candidate Optimization organization at Bristol Myers Squibb is a dynamic, multi-disciplinary department that works to discover and optimize new drug candidates. We work across all therapeutic areas and all modalities (small molecules, biotherapeutics, gene and cell therapies and other novel modalities), and engage with all other R&D functions to advance new assets in the BMS portfolio. Our integrated, cross-functional teams apply deep expertise in drug metabolism, pharmacokinetics (DMPK), toxicology, pharmaceutics and bioanalysis to identify and solve issues, discover high quality drug candidates, and enable their clinical development.

The Non-Clinical Safety and Veterinary Sciences organization enables the safe conduct of clinical studies and marketing applications while applying the core underlying principles of robust science & problem solving, 3R’s (reduce, replace and refine), animal welfare, and quality & compliance to our nonclinical efforts. While focusing on transforming patients’ lives through science, we intend to be an industry-leading nonclinical safety evaluation, laboratory animal science and medicine organization with high scientific, quality, and employee safety standards.

Chemistry is a core capability in Small Molecule and Drug Discovery (SMDD) with innovative scientists working in medicinal chemistry, radiochemistry, analytical chemistry and large-scale synthesis. Within SMDD, our Lead Discovery and Optimization (LDO) team is responsible for high throughput screening, compound storage and distribution, primary assays to support discovery programs, and compound profiling to explore drug liabilities in vitro.

Thematic Research Center Integrative Sciences (IS) has an external focus within the Research division at BMS. The IS group has three principal responsibilities: (i) creating Discovery Stage collaborations within the Biotech Ecosystem, (ii) facilitating conversion of academic concepts to industry workable ideas via incubator constructs, and (iii) supporting BMS scientists’ collaborations with academic investigators.

The Thematic Research Center Neuroscience is committed to development of transformational therapeutics for patients with neurodegenerative and neuromuscular diseases. We have built a network of external partnerships across multiple treatment modalities (small molecules, biologics and RNA targeting) that leverage our leadership in protein homeostasis and inflammation to attach neurological diseases. Internal research focuses on protein homeostasis by direct and ligand- directed degradation, neuroinflammation and remyelination.

The Oncogenesis Thematic Research Center at BMS is one of the fundamental research and early development engines delivering oncology therapeutics to patients. The Oncogenesis TRC has a major focus of exploiting BMS’ expertise in protein degradation to discover and develop therapies aimed at tumor intrinsic vulnerabilities and mechanisms of resistance to existing cancer therapeutics. This focus on protein degradation allows us to attack protein classes that were previously deemed undruggable.

The Pharmaceutical Candidate Optimization organization at Bristol Myers Squibb is a dynamic, multi-disciplinary department that works to discover and optimize new drug candidates. We work across all therapeutic areas and all modalities (small molecules, biotherapeutics, gene and cell therapies and other novel modalities), and engage with all other R&D functions to advance new assets in the BMS portfolio. Our integrated, cross-functional teams apply deep expertise in drug metabolism, pharmacokinetics (DMPK), toxicology, pharmaceutics and bioanalysis to identify and solve issues, discover high quality drug candidates, and enable their clinical development.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development, and across all therapeutic areas at BMS.

The Thematic Research Center Immunology and Cardiovascular (ICV) at BMS is one of the fundamental Research units delivering therapeutics to patients. Our mission is to create transformative medicines of tomorrow based on the cutting-edge science of today. We leverage BMS’s internal invention engine that includes industry-leading expertise in small molecule chemistry, protein biotherapeutics, cell therapy, protein degradation, nucleic acids, and other therapeutic modalities.

The Oncogenesis Thematic Research Center at BMS is one of the fundamental research and early development engines delivering oncology therapeutics to patients. The Oncogenesis TRC has a major focus of exploiting BMS’ expertise in protein degradation to discover and develop therapies aimed at tumor intrinsic vulnerabilities and mechanisms of resistance to existing cancer therapeutics. This focus on protein degradation allows us to attack protein classes that were previously deemed undruggable.

The Informatics and Predictive Sciences (IPS) mission is to Pioneer, Partner and Predict to drive transformative insights for patient benefit. IPS conducts applied computational research in areas that include genomic, structural and molecular informatics, computational and systems biology, patient selection and translational biomarker research, and broader fields including knowledge science, epidemiology and machine learning—across the full lifecycle of drug discovery and development, and across all therapeutic areas at BMS.

The Thematic Research Center Immuno-Oncology and Cell Therapy is one of the fundamental research engines delivering therapeutics to patients. Our mission is to drive leadership in the use of immune effector cell-based therapies in hematological and solid cancers. More specifically, we are focused on developing engineered cell-based therapies, as well as biotherapeutics, both aimed at harnessing the power of immune cells to mediate anti-tumor activity.